Can Therapy of Hepatitis C Affect the Development of Hepatocellular Carcinoma?

Author:
Laura M. Kulik From the Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Search for other papers by Laura M. Kulik in
Current site
Google Scholar
PubMed
Close
 MD
Full access

Chronic inflammation induced by viral infections and their role in carcinogenesis is well recognized. Two hepatotropic viruses, hepatitis B and hepatitis C (HCV), have been linked worldwide to the development of hepatocellular carcinoma (HCC). Although orthotopic liver transplant offers the best chance for cure and long-term survival, the demand for organs far outweighs the supply. The incidence of HCC in the United States has increased over the past 3 decades. HCV-induced cirrhosis is believed to play a significant role in the rising rate of HCC. Therefore, primary measures to prevent HCC in HCV-infected patients are urgently needed. Numerous studies of the HCV HCC patient have considered primary treatment with interferon-based therapy. However, secondary prevention currently seems to carry more promise. This article evaluates and assesses various treatments for primary and secondary chemoprevention in the setting of HCV.

Correspondence: Laura M. Kulik, MD, Assistant Professor, Feinberg School of Medicine, Northwestern University, 675 North St. Clair Street, Suite 15-250, Chicago, IL 60611. E-mail: LKulik@nmff.org
  • Collapse
  • Expand
  • 1.

    Coussens LM, Werb Z. Inflammation and cancer. Nature 2002;420:860867.

  • 2.

    Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet 2003;362:19071917.

  • 3.

    Bosch FX, Ribes J, Diaz M et al.. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5S16.

  • 4.

    El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745750.

  • 5.

    Lin S, Chu C. Secondary prevention of hepatitis c virus-related hepatocellular carcinoma [editorial]. J Gastroenterol Hepatol 2005;20:14751477.

  • 6.

    Yao FY, Bass NM, Nikolai B et al.. A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: implications for the current organ allocation policy. Liver Transpl 2003;9:684692.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 7.

    United Network for Organ Sharing (UNOS) Web site. Available at: http://www.UNOS.org. Accessed April 26, 2006.

    • PubMed
    • Export Citation
  • 8.

    Davis GL. Chronic hepatitis C and liver transplantation. Rev Gastroenterol Disord 2004;4:717.

  • 9.

    Chen CJ, Yang HI, Su J et al.. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. REVEAL-HBV Study Group. JAMA 2006;295:6573.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 10.

    Fattovich G. Progression of hepatitis B and C to hepatocellular carcinoma in western countries. Hepatogastroenterology 1998;45:12061213.

  • 11.

    De Mitri MS, Poussin K, Baccarini P et al.. HCV-associated liver cancer without cirrhosis. Lancet 1995;345:413415.

  • 12.

    Bralet MP, Regimbeau JM, Pineau P et al.. Hepatocellular carcinoma occurring in nonfibrotic liver: epidemiologic and histopathologic analysis of 80 French cases. Hepatology 2000;32:200204.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 13.

    Lee JS, Chu IS, Heo J et al.. Classification and prediction of survival in hepatocellular carcinoma by gene expression profiling. Hepatology 2004;40:667676.

  • 14.

    Niederau C, Lange S, Heintges T et al.. Prognosis of chronic hepatitis C: results of a large, prospective cohort study. Hepatology 1998;28:16871695.

  • 15.

    Yoshida H, Shiratori Y, Moriyama M et al.. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. IHIT Study Group. Inhibition of Hepatocarcinogenesis by Interferon Therapy. Ann Intern Med 1999;131:174181.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 16.

    Benvegnu L, Alberti A. Risk factors and prevention of hepatocellular carcinoma in HCV infection. Digest Dis Sci 1996;41;49S55S.

  • 17.

    Yano H, Iemura A, Haramaki M et al.. Interferon alfa receptor expression and growth inhibition by interferon alfa in human liver cancer cell lines. Hepatology 1999;29:17081717.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 18.

    Fattovich G, Stroffolini T, Zagni I et al.. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127(suppl 1):3550.

  • 19.

    McHutchison JG, Manns M, Patel K et al.. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002;123:10611069.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 20.

    Manns MP, McHutchison JG, Gordon SC et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001;358:958965.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 21.

    Hadziyannis SJ, Sette H Jr, Morgan TR et al.. PEGASYS International Study Group. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004;140:346355.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 22.

    Manns MP, McHutchison JG, Gordon SC et al.. Peginterferon alfa-2b plus ribavirin compared with interferon alpa-2b plus ribavirin for the initial treatment of chronic hepatitis C: a randomized trial. Lancet 2003;358:958965.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 23.

    Fried MW, Shiffman ML, Reddy R et al.. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C infection. N Engl J Med 2002;347:975982.

  • 24.

    Gale M Jr, Foy EM. Evasion of intracellular host defence by hepatitis C virus. Nature 2005;436:939945. Erratum in Nature 2005; 437:290.

  • 25.

    Nishiguchi S, Kuroki T, Nakatani S et al.. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet 1995;346:10511055.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 26.

    Azzaroli F, Accogli E, Nigro G et al.. Interferon plus ribavirin and interferon alone in preventing hepatocellular carcinoma: a prospective study on patients with HCV related cirrhosis. World J Gastroenterol 2004;10:30993102.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 27.

    Valla DC, Chevallier M, Marcellin P et al.. Treatment of hepatitis c virus-related cirrhosis: a randomized, control of interferon alfa-2b versus no treatment. Hepatology 1999;29:18701875.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 28.

    Bernardinello E, Cavalletto L, Chemello L et al.. Long-term clinical outcome after beta-interferon therapy in patients with chronic hepatitis C. TVVH Study Group. Hepatogastroenterology 1999;46:32163222.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 29.

    Okanoue T, Itaoh Y, Minami M et al.. Interferon therapy lowers the rate of progression to hepatocellular carcinoma in chronic hepatitis C but not significantly in an advanced stage: a retrospective study in 1148 patients. Viral Hepatitis Therapy Study Group. J Hepatol 1999;30:653659.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 30.

    Imai Y, Kawata S, Tamura S et al.. Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C. Osaka Hepatocellular Carcinoma Prevention Study Group. Ann Intern Med 1998;129:9499.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 31.

    Camma C, Di Bona D, Craxi A. The impact of antiviral treatments on the course of chronic hepatitis c: an evidence-based approach. Curr Pharm Des 2004;10:21232130.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 32.

    Baffis V, Shrier I, Sherker AH et al.. Use of interferon for prevention of hepatocellular cancer in cirrhotic patients with hepatitis B or hepatitis C infection. Ann Internal Med 1999;131:696701.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 33.

    Papatheodorisdis GV, Papadimitropoulos VC, Hadziyannis SJ. Effects of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001;15:689698.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 34.

    Shiratori Y, Ito Y, Yokosuka O et al.. Tokyo-Chiba Hepatitis Research Group. Antiviral therapy for cirrhotic hepatitis C: association with reduced hepatocellular carcinoma development and improved survival. Ann Intern Med 2005;142:105114.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 35.

    Shiratori Y, Yokosuka O, Nakata R et al.. Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA. Hepatology 1999;29:15731580.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 36.

    Shiratori Y, Moriyama M, Imazeki F et al.. A prospective study of interferon therapy modified by pre-treatment viral load in cirrhotic patients. Tokyo-Chiba Hepatitis Research Group. Liver 2000;20:271280.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 37.

    Yoshida H, Arakawa Y, Sata M et al.. Interferon therapy prolonged life expectancy among chronic hepatitis C patients. Gastroenterology 2002;123:483491.

  • 38.

    Bruix J, Sherman M. Management of hepatocellular carcinoma. Practice Guidelines Committee, American Association for the Study of Liver Diseases. Hepatology 2005;42:12081236.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 39.

    Ikeda K, Saitoh S, Koida I et al.. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 1993;18:4753.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 40.

    Tsukuma H, Hiyama T, Tanaka S et al.. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993;328:17971801.

  • 41.

    Murashima S, Tanaka M, Haramaki M et al.. A decrease in AFP level related to administration of interferon in patients with chronic hepatitis C and a high level of AFP. Dig Dis Sci 2006;51:808812.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 42.

    Di Bisceglie AM, Sterling RK, Chung RT et al.. HALT-C Trial Group. Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Study. J Hepatol 2005;43:434441.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 43.

    Saito Y, Saito H, Tada S et al.. Effect of long-term interferon therapy for refractory chronic hepatitis c: preventive effect on hepatocarcinogenesis. Hepatogastroenterology 2005;52:14911496.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 44.

    Afdhal N, Freilich B, Levine R et al.. Colchicine versus peg-interferon long term (COPILOT) trial: interim analysis of clinical outcomes at year 2. Hepatology 2004;40:238A. Abstract.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 45.

    Ikeda K, Arase Y, Saitoh S et al.. Interferon beta prevents recurrence of hepatocellular carcinoma after complete resection or ablation of the primary tumor- a prospective randomized study of hepatitis C virus-related liver cancer. Hepatology 2000;32:228032. Abstract.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 46.

    Suou T, Mitsuda A, Koda M et al.. Interferon alpha inhibits intrahepatic recurrence in hepatocellular carcinoma with chronic hepatitis C: a pilot study. Hepatol Res 2001;20:301311.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 47.

    Kubo S, Nishiguchi S, Hirohashi K et al.. Clinical significance of interferon therapy in treatments for hepatitis C virus-related hepatocellular carcinoma [Japanese]. Gan To Kagaku Ryoho 2001;28:19751979.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 48.

    Miyaguchi S, Watanabe T, Takahashi H et al.. Interferon therapy for hepatocellular carcinoma patients with low HCV-RNA levels. Hepatogastroenterology 2002;49:724729.

  • 49.

    Shiratori Y, Shiina S, Teratani T et al.. Interferon therapy after tumor ablation improves prognosis in patients with hepatocellular carcinoma associated with hepatitis C virus. Ann Intern Med 2003;138:299306.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 50.

    Lin SM, Lin CJ, Hsu CW et al.. Prospective randomized controlled study of interferon-alpha in preventing hepatocellular carcinoma recurrence after medical ablation therapy for primary tumors. Cancer 2004;100:376382.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 51.

    Bruix J. Hepatocellular Carcinoma. Barcelona, Spain: Mallorca; 2004.

  • 52.

    Hung CH, Lee CM, Wang JH et al.. Antiviral therapy after nonsurgical tumor ablation in patients with hepatocellular carcinoma associated with hepatitis C virus. J Gastroenterol Hepatol 2005;20:15531559.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 53.

    Gane EJ, Portmann BC, Naoumov NV et al.. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996;334:815820.

  • 54.

    Everson GT, Trotter J, Forman L et al.. Treatment of advanced hepatitis C with a low accelerating dosage regimen of antiviral therapy. Hepatology 2005;42:255262.

  • 55.

    National Institutes of Health. LADR protocol—a substudy of the Adult-to-Adult Living Donor Liver Transplant Cohort Protocol (A2ALL). Available at: http://www.nih-a2all.com. Accessed April 26, 2006.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 56.

    Ikeda M, Fujiyama S, Tanaka M et al.. Risk factors for development of hepatocellular carcinoma in patients with chronic hepatitis C after sustained response to interferon. Gastroenterol 2005;40:148156.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 57.

    Makiyama A, Itoh Y, Kasahara A et al.. Characteristics of patients with chronic hepatitis C who develop hepatocellular carcinoma after a sustained response to interferon therapy. Cancer 2004;101:16161622.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 58.

    Toyoda H, Kumada T, Hayashi K et al.. Characteristics and prognosis of hepatocellular carcinoma detected in sustained responders to interferon therapy for chronic hepatitis C. Yon-Ken HCV-HCC Follow-up Study Group. Cancer Detect Prev 2003;27:498502.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 59.

    Ikeda K, Kobayashi M, Saitoh S et al.. Recurrence rate and prognosis of patients with hepatocellular carcinoma that developed after elimination of hepatitis C virus RNA by interferon therapy. A closed cohort study including matched control patients. Oncology 2003;65:204210.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 60.

    Kensler TW, Egner PA, Wang JB et al.. Chemoprevention of hepatocellular carcinoma in aflatoxin endemic areas. Gastroenterol 2004;127(suppl 1):S310S318.

  • 61.

    Koga H. Hepatocellular carcinoma: is there a potential for chemoprevention using cyclooxygenase-2 inhibitors? Cancer 2003;98:661667.

Metrics

All Time Past Year Past 30 Days
Abstract Views 0 0 0
Full Text Views 318 229 10
PDF Downloads 74 27 6
EPUB Downloads 0 0 0